PCN92 THE WAR ON CANCER: AN ECONOMIC EVALUATION OF RECENT GAINS IN CANCER SURVIVAL
University of Chicago, Chicago, IL, USA OBJECTIVE: Cancer continues to be a leading cause of death, but the last few decades have seen many changes in the diagnosis and treatment of the disease. In this study, we estimate the economic value of gains in cancer survival over the last 20 years, separate these gains into the portions due to improvements in treatment and detection, and determine the extent to which the economic value of gains in cancer survival have been divided between patients and firms. METHODS: Using methodology developed by Philipson and Jena (2005) , we estimated the economic value of gains in cancer survival between 1990 and 2000. We then used estimates from the literature to calculate expenditures on cancer treatment, thereby allowing us to determine how the social value of gains in cancer treatment has been divided between patients and firms. RESULTS: The value of survival gains for all cancers combined was worth roughly $28,000-$30,000 per cancer patient, and most (78-88%) of this gain has been driven by improvements in treatment. For all cancers combined, improvements in cancer survival between 1990 and 2000 had a social value of roughly $1.6-$1.9 trillion, and health care providers were able to appropriate 6-19% of this total, with the rest accruing to patients. CONCLUSION: The social value of recent gains in cancer survival is very large. Most of this gain has been driven by improvements in cancer treatment, and has been appropriated by patients, not health care providers. . RESULTS: Evidence Based Medicine (I) is part of decision making through rigorous evidence reviews and the implicit rule that drugs must pass the threshold of effectiveness to be funded. Although drugs must pass one evidence threshold to be licenced in Canada, higher standards are required for reimbursement (e.g. phase III controlled trial data, peer reviewed publication). Health economic criteria (II) are assuming greater weight in decision making, as the review process is standardized, committee members become more economically literate, and a cancer pharmacoeconomics unit is established. The process of decision making (versus decision criteria) is evolving using the ethical foundations of Accountability for Reasonableness (III), important tenets of which are transparency, accountability, and stakeholder involvement in the decision process. Review of the 2006 decisions showed that 16 of 37 drugs were funded (43%). Among negative funding decisions 86% were characterized by inadequate evidence (main reason in 43%), 71% were characterized by cost effectiveness concerns (main reason in 15% ), and 5% by ethical concerns (main reason in 5%). Forty-eight percent of decisions were multifactorial. CONCLUSION: Each paradigm used to make cancer drug funding decisions comes from a distinct intellectual tradition. Most decisions in 2006 were based on more than one paradigm. We believe that optimal decision making for cancer drugs involves integrating concepts from all traditions, involving both distinct decision criteria and decision processes. Integration requires judicious tradeoffs between both efficiency and equity, and evidence quality and efficiency/equity. (197.xx, 198 .xx) for secondary metastases. Post-diagnosis prevalence of the key treatments was analyzed descriptively. Logistic regression was used to assess predictors of therapeutic choice. RESULTS: A total of 268 subjects were identified. Stage distribution was: IIB/C (18%); III (21%); IV (61%). 58% were Ն65 years of age and 62% were male. Surgery was the predominant treatment in stage IIB/C and III (received by >80% of subjects), but was seen in only 38% of stage IV patients. Across all stages, radiation, chemotherapy, and immunotherapy were less common (23%, 27%, and 10%, respectively). Being elderly [odds ratio = 2.19; 95% CI = (1.10-4.35)] and having stage IV disease [7.31 (2.38-22.39)] was associated with a significantly increased likelihood of receiving no active treatment. Older age (65+), higher co-comorbidity burden, and having stage IV disease were associated with a decreased probability of surgery 
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PCN95 CHANGE IN THE USE OF BREAST CONSERVING SURGERY BEFORE AND AFTER GUIDELINE PUBLICATION IN JAPAN
Fukuda H, Imanaka Y, Ishizaki T Kyoto University, Kyoto, Japan OBJECTIVE: Using 12 years of administrative data, we assessed the trends in the use of breast conserving surgery (BCS) before and after the release of clinical guidelines on BCS in Japan (published in 1999 and updated in 2005.) METHODS: We used a database from the Quality Improvement/Indicator Project that involved 40 teaching hospitals in Japan. Data on all discharged cases were collected from these hospitals from 1995. We then selected female operable breast cancer patients who were admitted to five of these hospitals from January 1996 through September 2007 (n = 1971). A multiple regression analysis was performed to examine whether the proportion of the use of BCS after publication of guidelines was higher than that before publication, after adjusted for the effects of patient's age, comorbidity status (Charlson Comorbidity Index), hospital, and time period of admission. The Hosmer-Lemeshow test was conducted to assess the goodness-of-fit of the model. RESULTS: The proportion of BCS use increased from 16.1% in 1996 to 62.2% in 2007. Multiple logistic regression analysis revealed that patients who were <50 years old (P < 0.001) and had no comorbidity (P < 0.001) were significantly more likely to receive BCS. The proportion of BCS use has been substantially higher since 2001, two years after the BCS guidelines were published in Japan. Significant practice variations of BCS use were also confirmed among hospitals. CONCLUSION: This study confirmed the lag time between guideline publication and change in practice of BCS use. We further need to examine the potential barriers to guideline adoption related to physicians' knowledge and attitudes as well as external barriers including patient-, guideline-, and environment-related factors, to explain the reasons of change in the use of BCS over ten years. [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] Medicare claims. Subjects Ն65 years with Ն1 stage IIB or higher melanoma diagnosis and Ն6 months of subsequent benefits coverage were selected. We documented utilization patterns of four major therapies (surgery, radiation, chemotherapy, immunotherapy) following the diagnosis. RESULTS: A total of 6470 subjects met all criteria. Stage distribution was: IIB/C (38%); IIIA/B (46%); IIIC (1%); IV (15%). Median follow-up was 56, 39, 16, and 6 months, respectively. Surgery (primarily tumor excision) was the predominant 1st line treatment, received by >85% of subjects with stage IIB/C, IIIA/B, or IIIC melanoma and 60% of stage IV cases, but was a rare 2nd line approach. Radiation was 1st line treatment in only 2%, 5%, and 13% of stage IIB/C, IIIA/B, and IIIC cases, respectively, but was more common as a 2nd line approach in these subjects (15%, 24%, and 41%, respectively). Radiation was equally prevalent (~30% of cases) as 1st or 2nd line treatment in stage IV. Chemotherapy was uncommon as 1st line treatment (<4% of all cases), but prevalent as 2nd line therapy (by respective stage, 14%, 20%, 41%, and 22% of cases). Immunotherapy was rare, except as 2nd line treatment in stage IIIC (26% of cases). CON-CLUSION: Beyond surgery as a 1st line approach, relatively few patients received other types of treatment as either 1st or 2nd line therapy. These findings demonstrate an unmet need in high risk and metastatic melanoma. Additional analyses of administrative data characterizing real-world treatment patterns in melanoma are needed to help inform the direction of future clinical trials. 
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